ArticleFrontiers in pharmacology2021

Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation.

Gang Shen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.